A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
| Title: | A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial |
|---|---|
| Authors: | Soo, R.A. a, Vervita, K. b, Früh, M. c, d, Cho, B.C. e, Majem, M. f, g, Rodriguez Abreu, D. h, g, Ribi, K. i, Callejo, A. g, j, Moran, T. g, k, Domine Gomez, M. l, g, Provencio, M. g, m, Addeo, A. n, Han, J.Y. o, Ortega Granados, A.L. p, g, Reck, M. q, Blasco, A. r, g, Garcia Campelo, R. s, g, Sala González, M.A. t, g, Britschgi, C. u, Roschitzki-Voser, H. i, Ruepp, B. i, Gasca-Ruchti, A. i, Haberecker, M. v, Dafni, U. d, w, Peters, S. x, Stahel, R.A. i, ⁎ |
| Source: | In Lung Cancer April 2025 202 |
| Database: | ScienceDirect |
| ISSN: | 01695002 |
|---|---|
| DOI: | 10.1016/j.lungcan.2025.108454 |
| Published in: | Lung Cancer |
| Language: | English |